DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the efficacy of induction treatment of
immunoterapy and chemotherapy depending on the resection status for the treatment of non
small cell lung cancer patients diagnosed with pancoast tumor.
The main objectives it aims to answer are:
- Complete resection rate after induction treatment with chemotherapy plus nivolumab
- Overall Survival and Progression Free Survival at 24 months
The sample size is 40 patients.